A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab in People With Follicular Lymphoma

Full Title

Purpose

Researchers are doing this study to see if the combination of epcoritamab, zanubrutinib, and rituximab works well against lymphoma. The people in this study have follicular lymphoma that has come back or keeps growing after treatment.

All three drugs are already used individually to treat lymphoma. Doctors hope that using them together will work better than each of them alone. Their use together is considered investigational. 

Who Can Join

To join this study, there are a few conditions. You must:

• Have follicular lymphoma that has come back or keeps growing after treatment.
• Have cancer that makes the CD20 protein.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Paola Ghione’s office at 646-608-4263.